← All trials
NCT02838069
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2016
- Primary completion
- Jan 1, 2019
- Completion date
- Jun 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 153
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- University of MontpellierLead sponsor
- Institut National de la Santé Et de la Recherche Médicale, FranceCollaborator
- University of ToulouseCollaborator
- EVANGELISCHES WALDKRANKENHAUS SPANDAU KRANKENHAUSBETRIEBSCollaborator
- Radboud UniversityCollaborator
- University of BolognaCollaborator
- University of PadovaCollaborator
- University of LyonCollaborator
- Cosmo PharmaceuticalsCollaborator
- PINTAIL LTDCollaborator
- Etablissement Français du SangCollaborator
- European Clinical Research Infrastructure NetworkCollaborator
- National University of IrelandCollaborator
- University of MontpellierOverall official - principal investigator
- University of UlmCollaborator
- University of CambridgeCollaborator
- University of ParisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.